EGFR ‐plasma mutations in prognosis for non‐small cell lung cancer treated with EGFR TKIs: A meta‐analysis

BACKGROUND: The plasma‐based epidermal growth factor receptor (EGFR) mutation testing is approved recently to use in clinical practice. However, it has not been used as a prognostic marker yet because of contradictory results. AIM: This meta‐analysis aims to clarify the role of the EGFR‐plasma test...

Descripción completa

Detalles Bibliográficos
Autores principales: Phan, Thang Thanh, Tran, Vinh Thanh, Tran, Bich‐Thu, Ho, Toan Trong, Pho, Suong Phuoc, Le, Anh Tuan, Le, Vu Thuong, Nguyen, Hang Thuy, Nguyen, Son Truong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351650/
https://www.ncbi.nlm.nih.gov/pubmed/34427045
http://dx.doi.org/10.1002/cnr2.1544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9351650/
https://www.ncbi.nlm.nih.gov/pubmed/34427045
http://dx.doi.org/10.1002/cnr2.1544

Ejemplares similares